Dopaminergic dysregulation in schizophrenia: A target for new drugs

Kenneth L. Davis; Michael Fiori; Bonnie M. Davis; Richard C. Mohs; Thomas B. Horvath; Michael Davidson

doi:10.1002/ddr.430090109

Dopaminergic dysregulation in schizophrenia: A target for new drugs

Kenneth L. Davis
, Michael Fiori
, Bonnie M. Davis
, Richard C. Mohs
, Thomas B. Horvath
, Michael Davidson

Research output: Contribution to journal › Article › peer-review

Abstract

The dopamine hypothesis postulates that at least some schizophrenic symptoms are a reflection of central nervous system hyperdopaminergia. The evidence for this model is briefly reviewed and its shortcomings highlighted. The dysregulation hypothesis of schizophrenia should be a useful reformulation. Rather than conceptualizing a static hyperdopaminergic state, schizophrenia might be better understood as a reflection of a relative failure of dopaminergic regulation. Evidence for such dysregulation is examined and possible mechanisms are presented. Avenues of future drug research are proposed.

Original language	English
Pages (from-to)	71-83
Number of pages	13
Journal	Drug Development Research
Volume	9
Issue number	1
DOIs	https://doi.org/10.1002/ddr.430090109
Publication status	Published - Sept 1986
Externally published	Yes

Keywords

DA — dopamine
GH — growth hormone
PGE — prostaglandin E
pHVA — plasma homovanillic acid

Access to Document

10.1002/ddr.430090109

Cite this

@article{89dcfd1d128742fb92296c3806c2f932,

title = "Dopaminergic dysregulation in schizophrenia: A target for new drugs",

abstract = "The dopamine hypothesis postulates that at least some schizophrenic symptoms are a reflection of central nervous system hyperdopaminergia. The evidence for this model is briefly reviewed and its shortcomings highlighted. The dysregulation hypothesis of schizophrenia should be a useful reformulation. Rather than conceptualizing a static hyperdopaminergic state, schizophrenia might be better understood as a reflection of a relative failure of dopaminergic regulation. Evidence for such dysregulation is examined and possible mechanisms are presented. Avenues of future drug research are proposed.",

keywords = "DA — dopamine, GH — growth hormone, PGE — prostaglandin E, pHVA — plasma homovanillic acid",

author = "Davis, \{Kenneth L.\} and Michael Fiori and Davis, \{Bonnie M.\} and Mohs, \{Richard C.\} and Horvath, \{Thomas B.\} and Michael Davidson",

year = "1986",

month = sep,

doi = "10.1002/ddr.430090109",

language = "English",

volume = "9",

pages = "71--83",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "John Wiley \& Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Dopaminergic dysregulation in schizophrenia

T2 - A target for new drugs

AU - Davis, Kenneth L.

AU - Fiori, Michael

AU - Davis, Bonnie M.

AU - Mohs, Richard C.

AU - Horvath, Thomas B.

AU - Davidson, Michael

PY - 1986/9

Y1 - 1986/9

N2 - The dopamine hypothesis postulates that at least some schizophrenic symptoms are a reflection of central nervous system hyperdopaminergia. The evidence for this model is briefly reviewed and its shortcomings highlighted. The dysregulation hypothesis of schizophrenia should be a useful reformulation. Rather than conceptualizing a static hyperdopaminergic state, schizophrenia might be better understood as a reflection of a relative failure of dopaminergic regulation. Evidence for such dysregulation is examined and possible mechanisms are presented. Avenues of future drug research are proposed.

AB - The dopamine hypothesis postulates that at least some schizophrenic symptoms are a reflection of central nervous system hyperdopaminergia. The evidence for this model is briefly reviewed and its shortcomings highlighted. The dysregulation hypothesis of schizophrenia should be a useful reformulation. Rather than conceptualizing a static hyperdopaminergic state, schizophrenia might be better understood as a reflection of a relative failure of dopaminergic regulation. Evidence for such dysregulation is examined and possible mechanisms are presented. Avenues of future drug research are proposed.

KW - DA — dopamine

KW - GH — growth hormone

KW - PGE — prostaglandin E

KW - pHVA — plasma homovanillic acid

UR - https://www.scopus.com/pages/publications/0023038725

U2 - 10.1002/ddr.430090109

DO - 10.1002/ddr.430090109

M3 - Article

AN - SCOPUS:0023038725

SN - 0272-4391

VL - 9

SP - 71

EP - 83

JO - Drug Development Research

JF - Drug Development Research

IS - 1

ER -

Dopaminergic dysregulation in schizophrenia: A target for new drugs

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this